Literature DB >> 6773974

Resistance of the ovary to blockade of aromatization with aminoglutethimide.

R J Santen, E Samojlik, S A Wells.   

Abstract

Aminoglutethimide (AG) is a potent inhibitor of aromatization in placental microsomes and in peripheral tissues in postmenopausal women. Aromatase inhibitors have been used to block estrogen production and induce breast tumor regression in rodents. To inhibit ovarian estrogen production, we administered various doses of AG and its highly potent D-stereoisomer to premenopausal women with breast carcinoma. However, at no dose level did AG consistently lower estrone and estradiol concentrations in plasma below those observed in normal menstruating women. Uniform increments in LH and FSH were also not observed. Only during the luteal phase were the levels of estradiol (but not estrone) significantly suppressed. These observations are best explained by the possibility that aromatase enzymes in the ovary, as opposed to those in the placenta and in peripheral tissues, are partially resistant to the effects of AG.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773974     DOI: 10.1210/jcem-51-3-473

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Hormonal therapy for primary breast cancer: scientific rationale and status of clinical research.

Authors:  Lisa E Sokolowicz; William J Gradishar
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 3.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

4.  The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D.

Authors:  J R Buchanan; R Santen; S Cauffman; A Cavaliere; R B Greer; L M Demers
Journal:  Calcif Tissue Int       Date:  1986-09       Impact factor: 4.333

Review 5.  Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

Authors:  L B Michaud; A U Buzdar
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

Review 6.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 7.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 8.  Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.

Authors:  R J Santen
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

Review 9.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

10.  Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Authors:  P E Lønning; S Kvinnsland; T Thorsen; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.